Kanada - angielski - Health Canada

astellas pharma canada inc - adenosine - solution - 3mg - adenosine 3mg - miscellaneous therapeutic agents

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

akorn - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine injection, usp is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: - second- or third-degree av block (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [see warnings and precautions (5.3)] - known hypersensitivity to adenosine injection [see warnings and precautions (5.7)] pregnancy category c . animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine can cause fetal harm when administered to pregnant women, adenosine should be used during pregnancy only if clearly needed. it is not known whether adenosine is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine in nursing infants, the decision to interrupt nursing after administration of adenosine or not to administer adenosine, should take into account the importance of the drug to the mother. the safety and effectiveness of adenosine in patients less than 18 years of age have not been established. clinical studies with adenosine injection did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients.

Belgia - angielski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hikma farmacêutica s.a. - adenosine 3 mg/ml - solution for injection - 6 mg/2 ml - adenosine 3 mg/ml - adenosine

Australia - angielski - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - adenosine, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - intravenous adenosine juno is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately.

Malta - angielski - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - adenosine - solution for infusion - adenosine 3 mg - cardiac therapy

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

henry schein, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - intravenous adenosine injection is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine injection administration. it is important to be sure the adenosine injection solution actually reaches the systemic circulation (see dosage and administration ). adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. intravenous adenosine injection is contraindicated in: 1.   second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). 2.   sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker). 3.   known hypersensitivity to adenosine.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adenosine 3 mg/ml (candida utilis lysed to get rna,then hydrolysed to adenosine);   - solution for injection - 6 mg/2ml - active: adenosine 3 mg/ml (candida utilis lysed to get rna,then hydrolysed to adenosine)   excipient: sodium chloride water for injection - adenocor is indicated for rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome), and as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias, and in sensitisation of intracavity electrophysiological investigations.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - adenosine 3 mg/ml (candida utilis lysed to get rna,then hydrolysed to adenosine) - solution for injection - 3 mg/10ml - active: adenosine 3 mg/ml (candida utilis lysed to get rna,then hydrolysed to adenosine) excipient: sodium chloride water for injection

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

northstar rx llc - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine injection, usp is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: - second- or third-degree av block (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [see warnings and precautions (5.3)] - known hypersensitivity to adenosine [see warnings and precautions (5.7)] pregnancy category c. animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should b

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: • second- or third-degree av block (except in patients with a functioning artificial pacemaker) [ see warnings and precautions ( 5-5.2)] • sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [ see warnings and precautions ( 5-5.2)] • known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [ see warnings and precautions ( 5-5.3)] • known hypersensitivity to adenosine injection [ see warnings and precautions ( 5-5.7)] 8.1 pregnancy animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosin